Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.45 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.45 |
| ▸ | RELA | Q04206 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.36 |
| ▸ | PLK4 | O00444 | 1/20 | 0.36 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.36 |
| ▸ | CDK1 | P06493 | 1/20 | 0.36 |
| ▸ | LYN | P07948 | 1/20 | 0.36 |
| ▸ | RET | P07949 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20448759 | 0.82 | LTA4H (0.43) | RAB9ANPC1SMN1; SMN2NPSR1MAP4K4 | |
| SCHEMBL19385063 | 0.79 | RAB9A (0.45) | RAB9ANPC1NFKB1NFKB2RELA | |
| SCHEMBL31588411 | 0.79 | CHEK1 (0.63) | RAB9ANPC1NFKB1NFKB2RELA | |
| SCHEMBL70602 | 0.79 | CHEK1 (0.63) | RAB9ANPC1NFKB1NFKB2RELA | |
| SCHEMBL5247445 | 0.78 | CNR2 (0.47) | RAB9ANPC1SMN1; SMN2MAPTMAP4K4 | |
| SCHEMBL10131002 | 0.76 | GRM5 (0.54) | — | |
| SCHEMBL27014322 | 0.76 | GRM5 (0.43) | RAB9ANPC1NFKB1NFKB2RELA | |
| SCHEMBL27914485 | 0.73 | LDHA (0.43) | RAB9ANPC1SMN1; SMN2L3MBTL1KDR | |
| SCHEMBL2317975 | 0.71 | DEGS1 (0.46) | RAB9ANPC1NFKB1NFKB2RELA | |
| SCHEMBL3146845 | 0.70 | NPC1 (0.54) | RAB9ANPC1NFKB1NFKB2RELA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3356387-B1 | ANTIMICROBIAL POLYMYXIN DERIVATIVE COMPOUNDS | UNIV MONASH (AU) | 2024-06-26 | — | — | EP | claimed |
| CN-108350034-B | Antimicrobial polymyxin derived compounds | 莫纳什大学 | 2022-03-11 | — | — | CN | claimed |
| US-11225505-B2 | Antimicrobial polymyxin derivative compounds | MONASH UNIVERSITY (AU) | 2022-01-18 | — | — | US | claimed |
| US-20180282374-A1 | ANTIMICROBIAL POLYMYXIN DERIVATIVE COMPOUNDS | MONASH UNIVERSITY (AU) | 2018-10-04 | — | — | US | claimed |
| EP-3356387-A1 | ANTIMICROBIAL POLYMYXIN DERIVATIVE COMPOUNDS | Monash University (AU) | 2018-08-08 | — | — | EP | claimed |
| EP-3356387-B1 | ANTIMICROBIAL POLYMYXIN DERIVATIVE COMPOUNDS | UNIV MONASH (AU) | 2024-06-26 | — | — | EP | disclosed |
| CN-108350034-B | Antimicrobial polymyxin derived compounds | 莫纳什大学 | 2022-03-11 | — | — | CN | disclosed |
| US-11225505-B2 | Antimicrobial polymyxin derivative compounds | MONASH UNIVERSITY (AU) | 2022-01-18 | — | — | US | disclosed |
| US-20180282374-A1 | ANTIMICROBIAL POLYMYXIN DERIVATIVE COMPOUNDS | MONASH UNIVERSITY (AU) | 2018-10-04 | — | — | US | disclosed |
| EP-3356387-A1 | ANTIMICROBIAL POLYMYXIN DERIVATIVE COMPOUNDS | Monash University (AU) | 2018-08-08 | — | — | EP | disclosed |
| EP-1301480-B1 | 1,3-DISUBSTITUTED AND 1,3,3-TRISUBSTITUTED PYRROLIDINES AS HISTAMINE-3 RECEPTOR LIGANDS AND THEIR THERAPEUTIC APPLICATIONS | ABBOTT LAB (US) | 2007-09-12 | — | — | EP | disclosed |
| US-20050113435-A1 | Histamine-3 receptor ligands for diabetic conditions | HANCOCK ARTHUR A (US) | 2005-05-26 | — | — | US | disclosed |
| WO-2003059341-A1 | 1,3-DISUBSTITUTED AND 1,3,3,-TRISUBSTITUTED PYRROLIDINES AS HISTAMINE-3 RECEPTOR LIGANDS AND THEIR THERAPEUTIC APPLICATIONS | ABBOTT LABORATORIES (US) | 2003-07-24 | — | — | WO | disclosed |
| WO-2003059342-A1 | HISTAMINE-3 RECEPTOR LIGANDS FOR DIABETIC CONDITIONS | ABBOTT LABORATORIES (US) | 2003-07-24 | — | — | WO | disclosed |
| US-20030134835-A1 | Histamine-3 receptor ligands for diabetes conditions | ABBOTT LABORATORIES | 2003-07-17 | — | — | US | disclosed |
| EP-1301480-A1 | 1,3-DISUBSTITUTED AND 1,3,3-TRISUBSTITUTED PYRROLIDINES AS HISTAMINE-3 RECEPTOR LIGANDS AND THEIR THERAPEUTIC APPLICATIONS | ABBOTT LABORATORIES (US) | 2003-04-16 | — | — | EP | disclosed |
| US-6515013-B2 | For diseases or conditions caused by or exacerbated by histamine-3 receptor activity | ABBOTT LABORATORIES | 2003-02-04 | — | — | US | disclosed |
| US-20020137931-A1 | 1,3-disubstituted and 1,3,3-trisubstituted pyrrolidines as histamine-3 receptor ligands and their therapeutic applications | ABBVIE INC. | 2002-09-26 | — | — | US | disclosed |
| US-20020035103-A1 | 1,3-Disubstituted and 1,3,3-trisubstituted pyrrolidines as histamine-3 receptor ligands and their therapeutic applications | ABBVIE INC. | 2002-03-21 | — | — | US | disclosed |
| WO-2002006223-A1 | 1,3-DISUBSTITUTED AND 1,3,3-TRISUBSTITUTED PYRROLIDINES AS HISTAMINE-3 RECEPTOR LIGANDS AND THEIR THERAPEUTIC APPLICATIONS | ABBOTT LABORATORIES (US) | 2002-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020137931-A1 | 1,3-disubstituted and 1,3,3-trisubstituted pyrrolidines as histamine-3 receptor ligands and their therapeutic applications | HRH3, HRH4, HRH1 | RAB9A 1738/4885NPC1 2137/4885NFKB1 2631/4885 |
| US-20020035103-A1 | 1,3-Disubstituted and 1,3,3-trisubstituted pyrrolidines as histamine-3 receptor ligands and their therapeutic applications | HRH3, HRH4, HRH1 | RAB9A 1738/4885NPC1 2137/4885NFKB1 2631/4885 |
| US-11225505-B2 | Antimicrobial polymyxin derivative compounds | VIP, PNKP, PEPD | RAB9A 3779/4885NPC1 2542/4885NFKB1 344/4885 |
| US-20180282374-A1 | ANTIMICROBIAL POLYMYXIN DERIVATIVE COMPOUNDS | VIP, PNKP, PEPD | RAB9A 3779/4885NPC1 2542/4885NFKB1 344/4885 |
| US-20050113435-A1 | Histamine-3 receptor ligands for diabetic conditions | HRH4, HRH2, HRH3 | RAB9A 2934/4885NPC1 3697/4885NFKB1 2749/4885 |
| US-20030134835-A1 | Histamine-3 receptor ligands for diabetes conditions | HRH4, HRH2, HRH3 | RAB9A 2929/4885NPC1 3440/4885NFKB1 2893/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.